Concepedia

Lokesh Jain

LJ

35

Publications

2.5K

Citations

24

H-Index

2007

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Center for Cancer Research

National Cancer Institute

Virginia Commonwealth University

National Institutes of Health

Lokesh Jain is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2007–2025

35

Publications

35

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski et al. · Journal of Clinical Oncology · 2008 · 336 citations · Full text

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

William L. Dahut, Charity D. Scripture, Edwin M. Posadas et al. · Clinical Cancer Research · 2008 · 178 citations

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 154 citations

, , +6

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

Lokesh Jain, Sukyung Woo, Erin R. Gardner et al. · British Journal of Clinical Pharmacology · 2011 · 142 citations · Full text

Rows per page

1–5 of 35